List of publications using PIK 90 (Axon 1362) purchased from Axon Medchem

(Total 13 publication citations listed; updated in JUNE 2016)

Costales, Abran Q., et al. "Compounds and compositions as protein kinase inhibitors." U.S. Patent No. 8,859,548. 14 Oct. 2014.
*PD0325901, PD184352, SL327, LY294002, PI103, PIK75, PIK90, GDC0941, BEX235, AS252424, TGX221 are from Axon Medchem
Schuler, Walter, Frank P. Stegmeier, and Markus Warmuth. "Use of a PKC inhibitor." U.S. Patent No. 8,748,428. 10 Jun. 2014.
* LY294002, PI103, PIK75, PIK90, AS252424, TGX221, GDC0941 are from Axon Medchem.

Control of Aβ release from human neurons by differentiation status and RET signaling.
D Scholz, Y Chernyshova, M Leist.
Neurobiol. Aging, 2013, 34 (1), 184–199. 

Tumor VEGF: VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.
S Chatterjee, LC Heukamp, M Siobal, J Schöttle, C Wieczorek, M Peifer, D Frasca, M Koker, K König, L Meder, D Rauh, R Buettner, J Wolf, RA Brekken, B Neumaier, G Christofori, K Thomas, RT Ullrich.
J. Clin. Invest. published online on Mar 1, 2013. doi:10.1172/JCI65385. 

AM Madera, D Poon, A Smith - U.S. Patent 20,130,096,149, issued April 18, 2013.
(10 drugs from Axon Medchem have been tested)
Read more:

Pais, Faye, et al. "Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity." Blood 122.21 (2013): 243-243.
*Ramapycin, PIK90, BEZ235 were purchased from Axon Medchem.

Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57Kip2.

DT Worster, T Schmelzle, NL Solimini, ES Lightcap, B Millard, GB Mills, JS Brugge, JG Albeck,
Sci. Signal. 2012, 5(214), ra19 (2012).  DOI: 10.1126/scisignal.2001986 

Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.
C Stengel, C W Cheung, J Quinn, K Yong, A Khwaja.
Leukemia 2012, 26(8), 1761-1770.  doi:10.1038/leu.2012.69 

Compounds and compositions as protein kinase inhibitors.
AQ Costales, S Huang, JX Jin, Z Liu, S Pecchi, D Poon, J Tellew, and Q Zhang.
U.S. Patent 8,242,260, issued August 14, 2012.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, S Chandarlapaty, B Markman, O Rodriguez, M Guzman, S Rodriguez, M Gili, M Russillo, JL Parra, S Singh, J Arribas, N Rosen, J Baselga.
Oncogene 2011, 30, 2547–2557.   doi:10.1038/onc.2010.626. 


Coordination between Extrinsic Extracellular Matrix Cues and Intrinsic Responses to Orient the Centrosome in Polarizing Cerebellar Granule Neurons.
SK Gupta, KF Meiri, K Mahfooz, U Bharti, and S Mani.
J. Neurosci. 2010, 30(7), 2755-2766.  doi: 10.1523/JNEUROSCI.4218-09.2010 

BacMam-Enabled LanthaScreen® Cellular Assays for PI3K/Akt Pathway Compound Profiling in Disease-Relevant Cell Backgrounds
CB Carlson, MJ Mashock, K Bi.
J. Biomol. Screen, 2010, 15 (3), 327-334. doi: 10.1177/1087057109357788 

FGF15/FGFR4 Integrates Growth Factor Signaling with Hepatic Bile Acid Metabolism and Insulin Action.
DJ Shin and TF Osborne.
J. Biol. Chem, 2009, 284, 11110-11120.  doi: 10.1074/jbc.M808747200 

 (This is an incomplete list, updated JUNE-2016) 

Please wait...